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New evidence has suggested the Rho
signaling pathway as a target for treat-
ment in acute spinal cord injury (SCI). The
Rho signaling pathway plays an impor-
tant role in neuronal growth inhibi-
tion after a CNS injury. Block of Rho
pathway is a new potential method to
improve recovery after an SCI. Other stud-
ies by our group had further revealed the
underlying mechanisms of this pathway
(Firouzi et al., 2011).
BA-210 (Trademarked as Cethrin) is
a newly designed Rho pathway antago-
nist. A “Phase I/IIa Clinical Trial of a
Recombinant Rho Protein antagonist in
Acute Spinal Cord Injury” by Fehlings
et al. (2011) has been recently published
to evaluate BA-210 specifically in course
of SCI. Implications of the findings of this
study can potentially change the manage-
ment of this condition around the world.
However, we would like to highlight some
concerns.
The article referenced two guideline
reviews on SCI and its spontaneous recov-
ery (Fawcett et al., 2007; Steeves et al.,
2007). They reported the results of recov-
ery after the application of BA-210 as
well. This may cause misinterpretation
when comparing their results with the
mentioned guidelines. Guidelines were
reviews of investigations including those
by Kirshblum et al. (2004), Waters et al.
(1993), Geisler et al. (2001) and European
Multicenter study in Spinal Cord Injury
(EMSCI). The first observations to note
are the differences between the study
groups. Excluding gunshots, stab wounds,
and transecting injuries in the current
study, leaves the only those patients who
are more likely to recover. The same occurs
in excluding patients who are more likely
to die in the following 6 months as well
as conditions that make patients unable or
unwilling to participate. Their criteria for
excluding selected patients raise the con-
cern that the study group was more likely
to recover spontaneously. Neither of the
above mentioned conditions was assigned
in the compared studies.
The current study reported 31% (5/16)
recovery from ASIA A to at least ASIA
C at cervical level of injury along with
6.3% (2/32) recovery at thoracic level.
They encountered an overall of recovery
of around 14.6% (7/48). The authors con-
sidered this to be encouraging. However,
we compared this to a meta-analysis by La
Rosa et al. They analyzed the summation
of at least 10 series of reports on patients
with complete SCI. Early decompression
was matched to the timing of surgery
in current study. In all, 42% (50/119) of
the patients were considered neurologi-
cally improved. Improvement was defined
by at least one grade progress according to
the Frankel’s scale; including both cervi-
cal and thoracic levels of injury. Although
42% recovery in La Rosa et al.’s meta-
analysis regards to advances from ASIA
A to B, it is still far behind 14.6%. This
can be a proper baseline and reference for
comparison; beside the 10% predicted rate
of conversion derived for untreated cervi-
cal SCI in the Fehlings et al.’s article (La
Rosa et al., 2004). Other studies insist on
the low rate of recovery after thoracic SCI.
However, T12 injuries are similar in nature
to L1 injuries rather than thoracic level
injuries. Separations of injuries on T12 are
still recommended to avoid over-reporting
in recoveries of thoracic SCI (Rahimi-
Movaghar, 2005; Rahimi-Movaghar et al.,
2006).
Fehlings et al. (2011) did not adjust the
results for dural tears. Dural tears were
reported in 31% of the patients. This can
be of importance in assessing Cethrin’s
tolerability and side effects. Moreover, it
can potentially affect the neurological out-
come after drug administration. Presence
of dural tears leaves the possibility of con-
founding effects intact.
Finally, can we expect a single applica-
tion of an agent in a proximate time to
the injury to declare further trend of “lin-
ear recovery” in its following 12 months?
Further investigations as well as phase
II and III clinical trials can answer this
question. Revealing the actual efficacy of
BA-210, particularly by a more inclusive
study group and an adjusted comparison
is needed.
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